This policy applies to activities that involve the secondary analysis of data (such as medical records, student records, data collected from previous studies, audio/video recordings, etc.) or ...
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy We identified published studies from 1983 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback